On Wednesday, Maxim (NASDAQ:MXIM) Group adjusted its outlook on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI), reducing the price target to $10 from the previous $30 while keeping a Buy rating ...
NEW YORK - BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a developer of cellular therapies for neurodegenerative diseases, announced Tuesday that it has regained compliance with Nasdaq's minimum ...
The company had received written notice from The Nasdaq Stock Market confirming that its common stock met the necessary bid price criteria. This development allows BrainStorm's stock to maintain ...
The lowered price target reflects these complex factors as the company moves forward with its ALS treatment research. In other recent news, BrainStorm Cell Therapeutics Inc. successfully regained ...